Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
A Study of ATRA in the Treatment of ITP
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04618328
- Locations
- 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China
Profiling the Skin Microbiome in Response to Altreno in Acne Patients
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT04548349
- Locations
- 🇺🇸
Beth Israel Deacones Medical Center, Boston, Massachusetts, United States
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 30
- Registration Number
- NCT04433169
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai, Shanghai, China
Opsin Receptors in Melasma
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Universidad Autonoma de San Luis Potosí
- Target Recruit Count
- 15
- Registration Number
- NCT04417348
- Locations
- 🇲🇽
Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 315
- Registration Number
- NCT04305054
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 2004), Los Angeles, California, United States
🇺🇸Providence Saint John's Health Center ( Site 2010), Santa Monica, California, United States
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT04305041
- Locations
- 🇮🇱
Chaim Sheba Medical Center ( Site 1701), Ramat Gan, Israel
🇫🇷A.P.H. Paris, Hopital Saint Louis ( Site 1107), Paris, France
🇫🇷Hopital Saint Andre ( Site 1108), Bordeaux, Gironde, France
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT04303169
- Locations
- 🇮🇹
Istituto Europeo di Oncologia ( Site 3301), Milano, Italy
🇮🇹Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena, Italy
🇺🇸The Angeles Clinic and Research Institute ( Site 3009), Los Angeles, California, United States
A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 170
- Registration Number
- NCT04241276
- Locations
- 🇬🇧
Barts NHS Trust, London, United Kingdom
The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04217148
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2023-10-19
- Target Recruit Count
- 112
- Registration Number
- NCT04113863
- Locations
- 🇮🇹
Ospedale Santa Maria della Misericordia di Udine, Udine, UD, Italy
🇮🇹ASST Papa Giovanni XXIII, Bergamo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.